← Back to Search

PRMT5 Inhibitor

PRT811 for Brain Tumor

Phase 1
Waitlist Available
Research Sponsored by Prelude Therapeutics
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
For subjects with recurrent high-grade glioma or GBM, must have biopsy proven evidence (WHO Grade III or IV) and received external bean fractionated radiotherapy and at least 2 cycles of adjuvant temozolomide chemotherapy. Mutant Glioma must comply with biomarker defined enrollment criterias.
For biomarker-selected solid tumors: must meet enrollment criteria
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline through approximately 2 years
Awards & highlights

Study Summary

This trial is testing a new cancer drug to see if it is safe and what the best dose is.

Eligible Conditions
  • Brain Tumor
  • Solid Tumors

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline through approximately 2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline through approximately 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
To describe dose limiting toxicities (DLT) of PRT811
To determine the maximally tolerated dose (MTD)
To determine the recommended phase 2 dose (RP2D) and schedule of PRT811
Secondary outcome measures
To describe any anti-tumor activity of PRT811
To describe the adverse event profile and tolerability of PRT811
To describe the pharmacokinetic profile of PRT811

Trial Design

1Treatment groups
Experimental Treatment
Group I: PRT811Experimental Treatment1 Intervention
PRT811 will be administered orally
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
PRT811
2019
Completed Phase 1
~90

Find a Location

Who is running the clinical trial?

Prelude TherapeuticsLead Sponsor
8 Previous Clinical Trials
569 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many participants are being accepted into this medical research?

"Indeed, clinicaltrials.gov provides evidence that this medical trial is actively looking for participants. It was initially posted on November 6th 2019 and the most recent modifications were made on November 28th 2022. The investigation requires 145 subjects across 10 centres to be enrolled ."

Answered by AI

Where are the available facilities for participating in this clinical investigation?

"10 clinical trial sites are currently accepting patients for the study. In addition to New Haven, Saint Louis and Augusta, there are 7 other locations available. To minimise travel costs, it is advisable to select a clinic located nearby when enrolling in this trial."

Answered by AI

Is enrollment still available for this research endeavor?

"Affirmative. The details available on clinicaltrials.gov reveal that this investigation is presently searching for participants, having been initially posted on November 6th 2019 and most recently edited on the 28th of November 2022. A total of 145 patients from 10 medical centres must be enrolled to complete the trial."

Answered by AI

Has the FDA sanctioned PRT811 for public consumption?

"PRT811's safety score is a 1 because of the limited clinical data that supports its efficacy and safety."

Answered by AI
~16 spots leftby Mar 2025